In an official statement, the CCI said the proposed transaction involves the acquisition of 100% per cent shareholding of Bharat Serums and Vaccines Limited (BSV) by Mankind Pharma Ltd (Proposed Combination).

The CCI has cleared Mankind Pharma's proposed acquisition of 100% stake in Bharat Serums and Vaccines for ₹13,630 crore.

Mankind Pharma Ltd. receives regulatory approvals for 100% acquisition of Bharat Serums and Vaccines Ltd. worth ₹13,630 crore.

Deal involves Mankind buying 100 per cent equity in Bharat Serums from PE firm Advent International at an enterprise value of ₹13,630 crore

In a regulatory filing to stock exchanges today, Mankind Pharma Ltd, the fourth-largest pharmaceutical company in India by market share, said that its board has approved raising up to Rs 5,000 crore through non-convertible debentures in 3-4 distinct series with maturities of upto 48 months.

The Competition Commission of India has approved Mankind Pharma's ₹13,630 crore acquisition of Bharat Serums and Vaccines.

In July this year, Mankind Pharma announced that it will fully acquire Bharat Serums and Vaccines from private equity firm Advent International for around Rs 13,630 crore.

The company's board of directors on Monday approved raising up to Rs 5,000 crore via non-convertible debentures in 3-4 distinct series with maturities of up to 48 months, in a regulatory filing to stock exchanges.